Skip to main content
. 2017 Feb 17;8(11):18312–18321. doi: 10.18632/oncotarget.15436

Figure 5. NPC-26 inhibits HCT-116 tumor growth in SCID mice.

Figure 5

Same amount (5 million per mouse) of HCT-116 cells expressing scramble control shRNA (“sc-shRNA”) or AMPKα1 shRNA (“Seq1”) were inoculated to the SCID mice to establish xenografted tumors. Mice were administrated with NPC-26 (25 mg/kg, daily, i.p.) or saline (“Vehicle”) for a total of 30 days, tumor volume A. and mice body weight D. were recorded every 5 days. Twelve hours after initial NPC-26 administration, one tumor of each group was isolated, and expression of listed proteins was tested by Western blot assay B. or IHC staining assay C. * p <0.05 vs. “Vehicle”. # p <0.05 vs. NPC-26 treatment of “sc-shRNA” tumors. Bar=100 μm (C).